Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,296.29 -2,013.75 (-3.04%) CMC Crypto 200
1,385.35 -38.75 (-2.72%)
Iterum Therapeutics plc (ITRM)
| Previous close | 1.5800 |
| Open | 1.6000 |
| Bid | 1.4900 x 100 |
| Ask | 1.6000 x 100 |
| Day's range | 1.5100 - 1.6000 |
| 52-week range | 0.6220 - 2.5000 |
| Volume | |
| Avg. volume | 625,772 |
| Market cap | 25.462M |
| Beta (5Y monthly) | 2.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.9600 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.50 |
Insider MonkeyIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript March 28, 2024 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.94, expectations were $-1.02. ITRM isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, everyone, and welcome to the […]
- Thomson Reuters StreetEvents
Q4 2023 Iterum Therapeutics PLC Earnings Call
Q4 2023 Iterum Therapeutics PLC Earnings Call
GlobeNewswireIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r
